Studies indicate that ingested oral cyanocobalamin tablets are ineffective in the treatment of allergic disease, saw palmetto berry perhaps because once ingested, they are directly metabolized in the liver. when b12 is delivered via injection or lozenge it passes throughout the bloodstream palmetto before arriving at the liver. it is during this first pass in its native form that it is believed to exert berry and saw its therapeutic effect. clinical research: "the world health organization (who) recognizes allergic rhinitis (hay fever), sinusitis, asthma,...conjunctivitis, urticaria, eczema, dermatitis (contact palmetto and atopic)...allergic and migraine headache...as diseases in which ige-mediated allergy may be involved."1 in 1988, asthma and allergic rhinitis subjects were treated with b12. total ige, specific ige and pulmonary lung functions were taken at days 45, 150 and 180 from baseline. eight of the 9 subjects had reduced ige. 2 in 1989 open label studies at two sites in riverside county, ca in 1989. sixteen berry of the 17 subjects had lowered saw ige levels from day 0 to day 30.3

genentech and novartis are developing an anti-ige monoclonal antibody for asthma and allergic rhinitis. in december 1999 they announced positive study results. this is evidence that reducing ige results in a reduction of symptoms associated with palmetto ige-mediated allergic disease.13 for people who find they cannot adequately avoid the allergens, the symptoms often can be controlled with medications. effective medications that can be prescribed by a physician include berry antihistamines, topical nasal steroids, and cromolyn sodium - any of which can be used alone or in combination. many effective antihistamines and decongestants also are available without a prescription. saw and palmetto click here for allergy medication online.

all of the active b12 group reporting showed reduction in severity of symptoms berry ranging from 31% to 70%, while the placebo controls reported either no change or a worsening of symptoms. wilcoxon-rank of .002 for the end-points of saw sneezing, nasal congestion and runny nose; and p = .005 for ige reductions. in 1992, the above mentioned data from 1988 on were presented by dr. o''connor to the fda. the fda panel acknowledged the safety of the treatment. the panel seemed to be in agreement that the statistics indicated a significant reduction palmetto in ige and that a quantitative drop in symptoms was demonstrated. in 1992, belen anibarro, berry md, studied five children with asthma with metabisulfite intolerance confirmed by oral challenge testing. the test was repeated after premedication with 1.5 mg of oral cyanocobalamin. in four of the five patients treated, bronchospasm did not develop in the second metabisulfite challenge.6